Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


15.10.2018

1 Am J Dermatopathol
5 Ann Surg Oncol
1 Biochem Biophys Res Commun
1 Cancer
1 Cancer Res
4 J Am Acad Dermatol
1 J Immunother
2 Melanoma Res
2 Nat Med
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Dermatopathol

  1. KO JS, Gastman BR, Conic R, Tellez Diaz Trujillo A, et al
    Decreased T-Cell Programmed Death Receptor-1 Expression in Pregnancy-Associated Melanoma.
    Am J Dermatopathol. 2018 Oct 9. doi: 10.1097/DAD.0000000000001286.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  2. HIEKEN TJ, Kane JM 3rd, Wong SL
    The Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma.
    Ann Surg Oncol. 2018 Oct 3. pii: 10.1245/s10434-018-6812.
    PubMed     Text format     Abstract available

  3. PEREZ MC, Miura JT, Naqvi SMH, Kim Y, et al
    Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience.
    Ann Surg Oncol. 2018 Oct 8. pii: 10.1245/s10434-018-6803.
    PubMed     Text format     Abstract available

  4. LOWE MC, Farley CR, Delman KA
    ASO Author Reflections: Optimizing the Outcomes for Patients: The Evolution of the Management of Regional Disease in Patients with Melanoma.
    Ann Surg Oncol. 2018 Oct 8. pii: 10.1245/s10434-018-6857.
    PubMed     Text format    

  5. MURTHA TD, Han D
    ASO Author Reflections: Factors that Predict Performance of Sentinel Lymph Node Biopsy and the Association with Improved Survival for Melanoma Patients Who Have Nodal Staging.
    Ann Surg Oncol. 2018 Oct 9. pii: 10.1245/s10434-018-6841.
    PubMed     Text format    

  6. EGGER ME, McMasters KM
    ASO Author Reflections: The Sentinel Lymph Node in Melanoma: Now More Important Than Ever.
    Ann Surg Oncol. 2018 Oct 11. pii: 10.1245/s10434-018-6855.
    PubMed     Text format    


    Biochem Biophys Res Commun

  7. KIM DH, Kim KS, Ramakrishna S
    NFAT5 promotes in vivo development of murine melanoma metastasis.
    Biochem Biophys Res Commun. 2018 Oct 4. pii: S0006-291X(18)32110.
    PubMed     Text format     Abstract available


    Cancer

  8. TARHINI AA, Frankel P, Ruel C, Ernstoff MS, et al
    NCI 8628: a randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.
    Cancer. 2018 Oct 10. doi: 10.1002/cncr.31734.
    PubMed     Text format     Abstract available


    Cancer Res

  9. RAVINDRAN MENON D, Luo Y, Arcaroli JJ, Liu S, et al
    CDK1 interacts with Sox2 and promotes tumor initiation in human melanoma.
    Cancer Res. 2018 Oct 8. pii: 0008-5472.CAN-18-0330.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  10. WALTON KE, Garfield EM, Zhang B, Quan VL, et al
    The role of TERT promoter mutations in differentiating recurrent nevi from recurrent melanomas: a retrospective, case-control study.
    J Am Acad Dermatol. 2018 Oct 1. pii: S0190-9622(18)32640.
    PubMed     Text format     Abstract available

  11. CAI ED, Swetter SM, Sarin KY
    Association of multiple primary melanomas with malignancy risk: a population-based analysis of the Surveillance, Epidemiology, and End Results Program database from 1973-2014.
    J Am Acad Dermatol. 2018 Oct 1. pii: S0190-9622(18)32637.
    PubMed     Text format     Abstract available

  12. PINERO-MADRONA A, Gomez-Ruiz AJ, Ruiz-Merino G, Martinez-Barba E, et al
    Prognostic value of the Breslow/diameter ratio in cutaneous melanoma.
    J Am Acad Dermatol. 2018 Oct 1. pii: S0190-9622(18)32644.
    PubMed     Text format    

  13. ALTIERI L, Eguchi M, Peng DH, Cockburn M, et al
    Predictors of mucosal melanoma survival in a population-based setting.
    J Am Acad Dermatol. 2018 Oct 5. pii: S0190-9622(18)32670.
    PubMed     Text format     Abstract available


    J Immunother

  14. LINDENBERG MA, Retel VP, van den Berg JH, Geukes Foppen MH, et al
    Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product.
    J Immunother. 2018;41:413-425.
    PubMed     Text format     Abstract available


    Melanoma Res

  15. PETRELLI F, Ardito R, Merelli B, Lonati V, et al
    Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis.
    Melanoma Res. 2018 Oct 10. doi: 10.1097/CMR.0000000000000520.
    PubMed     Text format     Abstract available

  16. DABROSIN N, Sloth Juul K, Baehr Georgsen J, Andrup S, et al
    Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.
    Melanoma Res. 2018 Oct 5. doi: 10.1097/CMR.0000000000000515.
    PubMed     Text format     Abstract available


    Nat Med

  17. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
    Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
    Nat Med. 2018 Oct 8. pii: 10.1038/s41591-018-0197.
    PubMed     Text format     Abstract available

  18. BLANK CU, Rozeman EA, Fanchi LF, Sikorska K, et al
    Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
    Nat Med. 2018 Oct 8. pii: 10.1038/s41591-018-0198.
    PubMed     Text format     Abstract available


    PLoS One


  19. Retraction: MicroRNA-143 Targets Syndecan-1 to Repress Cell Growth in Melanoma.
    PLoS One. 2018;13:e0205767.
    PubMed     Text format    

  20. ISHIMURA ME, Teixeira D, Silveira GDP, Gambero M, et al
    Killed Propionibacterium acnes enhances immunogenicity and tumor growth control of a dendritic-tumor cell hybrid vaccine in a murine melanoma model.
    PLoS One. 2018;13:e0205148.
    PubMed     Text format     Abstract available

  21. DEBNIAK T, Scott RJ, Gorski B, Masojc B, et al
    BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population.
    PLoS One. 2018;13:e0204768.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: